The deal covers Circulogene's technology for enriching tumor DNA from small volumes of blood for next-generation sequencing-based analysis.
The company's assay relies on proprietary methods of DNA isolation that enable analysis of cell-free DNA from finger-stick volume blood samples.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.